P Anagnostis1, K Boboridis2, F Adamidou3, M Kita3. 1. Department of Endocrinology and Diabetes, Hippokration Hospital of Thessaloniki, Sarantaporou 10, 54640, Thessaloníki, Greece. anagnwstis.pan@yahoo.gr. 2. 1st University Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloníki, Greece. 3. Department of Endocrinology and Diabetes, Hippokration Hospital of Thessaloniki, Sarantaporou 10, 54640, Thessaloníki, Greece.
Abstract
BACKGROUND/AIMS: The natural course of Graves' orbitopathy (GO) has been poorly documented. The aim of this review is to provide current knowledge regarding the natural course of mild GO, trying to address the issue of whether and to what extent it constitutes a chronic remitting or transient disease. METHODS: We systematically searched PubMed for English language publications until August 2016 under the following terms: "Graves' orbitopathy" OR "Graves' ophthalmopathy" OR "thyroid eye disease" AND "natural course" OR "natural history". RESULTS: Few studies have investigated the course of mild orbital disease in patients with GO. Large controlled trials are lacking and data can be extracted mainly from small retrospective and some prospective studies, after excluding patients who had received radioiodine for thyrotoxicosis or surgical treatment for GO. In general, more than half of GO patients may show spontaneous improvement in their clinical features, whereas no safe conclusions can be drawn with regard to complete resolution, with percentages ranging from 6 to 58 %. CONCLUSIONS: The question whether mild GO is a remitting, albeit chronic disease, or even a transient event in the course of Graves' disease, remains currently unanswered.
BACKGROUND/AIMS: The natural course of Graves' orbitopathy (GO) has been poorly documented. The aim of this review is to provide current knowledge regarding the natural course of mild GO, trying to address the issue of whether and to what extent it constitutes a chronic remitting or transient disease. METHODS: We systematically searched PubMed for English language publications until August 2016 under the following terms: "Graves' orbitopathy" OR "Graves' ophthalmopathy" OR "thyroid eye disease" AND "natural course" OR "natural history". RESULTS: Few studies have investigated the course of mild orbital disease in patients with GO. Large controlled trials are lacking and data can be extracted mainly from small retrospective and some prospective studies, after excluding patients who had received radioiodine for thyrotoxicosis or surgical treatment for GO. In general, more than half of GO patients may show spontaneous improvement in their clinical features, whereas no safe conclusions can be drawn with regard to complete resolution, with percentages ranging from 6 to 58 %. CONCLUSIONS: The question whether mild GO is a remitting, albeit chronic disease, or even a transient event in the course of Graves' disease, remains currently unanswered.
Authors: C Marcocci; G Bruno-Bossio; L Manetti; M L Tanda; P Miccoli; P Iacconi; M P Bartolomei; M Nardi; A Pinchera; L Bartalena Journal: Clin Endocrinol (Oxf) Date: 1999-10 Impact factor: 3.478
Authors: M L Tanda; E Piantanida; L Liparulo; G Veronesi; A Lai; L Sassi; N Pariani; D Gallo; C Azzolini; M Ferrario; L Bartalena Journal: J Clin Endocrinol Metab Date: 2013-02-13 Impact factor: 5.958
Authors: G Lanzolla; E Sabini; M A Profilo; B Mazzi; A Sframeli; R Rocchi; F Menconi; M Leo; M Nardi; P Vitti; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2018-06-19 Impact factor: 4.256
Authors: G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2017-12-18 Impact factor: 4.256
Authors: G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2017-06-27 Impact factor: 4.256
Authors: Elena Sabini; Marenza Leo; Barbara Mazzi; Roberto Rocchi; Francesco Latrofa; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò Journal: Eur Thyroid J Date: 2017-06-26
Authors: S Sellari-Franceschini; R Rocchi; M Marinò; A Bajraktari; B Mazzi; G Fiacchini; P Lepri; I Dallan; P Vitti; C Marcocci Journal: J Endocrinol Invest Date: 2018-02-15 Impact factor: 4.256